SCHEMBL4698145

SCHEMBL4698145

CCCCN1CCCC(Oc2ncnc3oc(-c4ccccc4)c(-c4ccc(OC)cc4)c23)C1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TNK2 Q07912 9/20 0.49
KDM4E B2RXH2 6/20 0.49
ALDH1A1 P00352 6/20 0.49
HPGD P15428 5/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
UBE2N P61088 1/20 0.49
HSD17B10 Q99714 4/20 0.48
MAPT P10636 4/20 0.48
NPSR1 Q6W5P4 3/20 0.48
USP2 O75604 3/20 0.48
TP53 P04637 3/20 0.48
KMT2A Q03164 3/20 0.48
MEN1 O00255 2/20 0.48
POLB P06746 1/20 0.48
RAD52 P43351 1/20 0.48
LCK P06239 7/20 0.47
KDR P35968 4/20 0.47
EGFR P00533 2/20 0.47
SRC P12931 2/20 0.47
ZAP70 P43403 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4753075 0.95 KDM4E (0.51) TNK2KDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL4789353 0.91 TNK2 (0.44) TNK2KDM4EALDH1A1HPGDHSD17B10
SCHEMBL4750471 0.91 TNK2 (0.47) TNK2KDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL12607061 0.91 TNK2 (0.47) TNK2KDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL1787960 0.90 TNK2 (0.48) TNK2KDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL1786593 0.89 TNK2 (0.48) TNK2KDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL1787327 0.89 TNK2 (0.48) TNK2KDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL12607170 0.89 TNK2 (0.48) TNK2KDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL1785467 0.89 TNK2 (0.48) TNK2KDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL12607137 0.88 TNK2 (0.49) TNK2KDM4EALDH1A1HPGDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008131859-A2 USE OF CYCLICALLY SUBSTITUTED FUROPYRIMIDINE DERIVATIVES FOR TREATING PULMONARY ARTERIAL HYPERTONIA BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2008-11-06 WO disclosed
EP-1966218-A1 NOVEL, CYCLIC SUBSTITUTED FUROPYRIMIDINE DERIVATIVES AND USE THEREOF FOR TREATING CARDIOVASCULAR DISEASES Bayer HealthCare AG (DE) 2008-09-10 EP disclosed
WO-2007079861-A1 NOVEL, CYCLIC SUBSTITUTED FUROPYRIMIDINE DERIVATIVES AND USE THEREOF FOR TREATING CARDIOVASCULAR DISEASES BAYER HEALTHCARE AG (DE) 2007-07-19 WO disclosed